Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by eric40on Apr 08, 2019 10:35pm
190 Views
Post# 29599886

RE:my hope is they convert

RE:my hope is they convertGoBBs, IMHO,  if Thomvest convert 60 millions$ of dept into shares at 15 cents, this is 400 millions shares of dilution and no money (depth conversion, not equity financing) . If Thomvest comes to an agreement to convert shares a 1 to 1 dept equity, this means that the bank/fund that will provide the money needed (50 to 70 millions$, let say 60 million$) will provide 1 dollar of fresh cash for every dollar of dept converted into shares. So to get 60 millions of fresh cash needed to hopefully get to the BLA of Ryplazim, there will be 400 millions new shares for the 60 millions$ dept convertion from Thomvest and 400 millions shares issued to the provider of the 60 millions$ of fresh cash, for a total of 800 millions new shares on top of the actual 739 millions shares on the float for a grand total of 1 539 000 000 shares (1.5 billions) it is far more than 1.1 billion and from what was said at the CC, all banks and fund approach for a new financing wants most or all the dept converted into shares and Thomvest wants someone else then them to finance Prometic. So they will have to come to an agreement where both parties feel confortable with there investment. This probably translate in the lower share price possible. Hopefully, 15.5 cents will be lower enough as in the last thomvest agreement for the last two financing (10 and 5 millions recently).  It will already be painfull a lot for most shareholders. 
Bullboard Posts